| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,541 | -3,465 |
| Depreciation and amortization | 24 | 9 |
| Inventory reserve | 0 | -4 |
| Amortization of discount of notes payable and convertible notes payable | 369 | 227 |
| Foreign exchange adjustments | -139 | -211 |
| Tax benefit recognized on unrealized gain on debt securities | 13 | 591 |
| Realized loss on investment in convertible bond | -531 | -531 |
| Loss on debt extinguishment | -672 | -376 |
| Gain on lease modification | 861 | 861 |
| Share-based compensation | 18 | 9 |
| Change in fair value of warrant derivative liabilities | -3 | -5 |
| Change in fair value of conversion feature derivative, notes payable | 162 | 162 |
| Accounts receivable | -4 | -552 |
| Inventories | -428 | -319 |
| Prepaid expenses and other current assets | -460 | -376 |
| Other non-current assets | -333 | -302 |
| Accounts payable and accrued expenses | 4,878 | 2,464 |
| Other current liabilities | -2,682 | -2,516 |
| Other long-term liabilities | -820 | -419 |
| Net cash flows used in operating activities | -2,220 | -2,629 |
| Proceeds from sale of convertible bond | 2,172 | 2,172 |
| Purchases of property and equipment | 1 | 1 |
| Net cash flows provided by investing activities | 2,171 | 2,171 |
| Proceeds from notes payable issued | 4,562 | 3,238 |
| Payments of notes payable | 5,175 | 2,849 |
| Payments of notes payable, related party | 240 | 240 |
| Payments of convertible notes | 210 | 210 |
| Net cash flows used in financing activities | -1,063 | -61 |
| Effect of exchange rate changes on cash | 16 | 15 |
| Net decrease in cash and cash equivalents | -1,096 | -504 |
| Cash and cash equivalents at beginning of period | 1,389 | - |
| Cash and cash equivalents at end of period | 293 | - |
Emmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc. (EMMA)